(Q38042110)

27 August 2017

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease (English)

1 reference

27 August 2017

cardiovascular disease

1 reference

1 reference

Usha Panchapakesan

1

1 reference

27 August 2017

Amanda Mather

series ordinal

2

1 reference

27 August 2017

Carol Pollock

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

27 August 2017

1 reference

27 August 2017

124

1 reference

27 August 2017

1

1 reference

27 August 2017

17-26

1 reference

Novel aspects of cellular action of dipeptidyl peptidase IV/CD26.

27 August 2017

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Peptidomics of the prolyl peptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The evolving place of incretin-based therapies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Tubulointerstitial changes as a major determinant in the progression of renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The multifunctional or moonlighting protein CD26/DPPIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Peptidase substrates via global peptide profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Liver dipeptidyl aminopeptidase IV hydrolyzes substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The astacin family of metalloendopeptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Meprin beta metalloprotease gene polymorphisms associated with diabetic nephropathy in the Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Meprin A, the major matrix degrading enzyme in renal tubules, produces a novel nidogen fragment in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Generation of biologically active interleukin-1beta by meprin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemia-reperfusion injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Meprin, a brush-border enzyme, plays an important role in hypoxic/ischemic acute renal tubular injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Meprin activity in rats with experimental renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

HMGB1 contributes to kidney ischemia reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Potential manipulation of endothelial progenitor cells in diabetes and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120167

21 January 2018

Identifiers

DOI

10.1042/CS20120167

1 reference

27 August 2017

1 reference